Business Description
MaxCyte Inc
NAICS : 334510
SIC : 3845
ISIN : US57777K1060
Total Employee Number:
91Description
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.13 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -0.58 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 1.33 | |||||
Beneish M-Score | -2.95 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -10.7 | |||||
3-Year EBITDA Growth Rate | -15.8 | |||||
3-Year EPS without NRI Growth Rate | -15.9 | |||||
3-Year FCF Growth Rate | -1.3 | |||||
3-Year Book Growth Rate | -13.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 14.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.82 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 81.76 | |||||
9-Day RSI | 68.9 | |||||
14-Day RSI | 61.72 | |||||
3-1 Month Momentum % | 34.43 | |||||
6-1 Month Momentum % | 105 | |||||
12-1 Month Momentum % | 17.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 12.26 | |||||
Quick Ratio | 11.47 | |||||
Cash Ratio | 10.68 | |||||
Days Inventory | 435.96 | |||||
Days Sales Outstanding | 60.49 | |||||
Days Payable | 77.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.4 | |||||
Shareholder Yield % | 0.52 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 79.23 | |||||
Operating Margin % | -113.3 | |||||
Net Margin % | -114.77 | |||||
EBITDA Margin % | -95.94 | |||||
FCF Margin % | -76.6 | |||||
OCF Margin % | -73.98 | |||||
ROE % | -20.5 | |||||
ROA % | -17.56 | |||||
ROIC % | -40.99 | |||||
3-Year ROIIC % | -45.38 | |||||
ROC (Joel Greenblatt) % | -103.98 | |||||
ROCE % | -18.46 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.57 | |||||
PB Ratio | 0.89 | |||||
Price-to-Tangible-Book | 0.89 | |||||
EV-to-EBIT | -1.37 | |||||
EV-to-EBITDA | -1.62 | |||||
EV-to-Revenue | 1.56 | |||||
EV-to-Forward-Revenue | 5.06 | |||||
EV-to-FCF | -2.03 | |||||
Price-to-GF-Value | 0.56 | |||||
| Price-to-Net-Current-Asset-Value | 1.48 | |||||
| Price-to-Net-Cash | 1.76 | |||||
Earnings Yield (Greenblatt) % | -72.99 | |||||
FCF Yield % | -17.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MaxCyte Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 26.711 | ||
| EPS (TTM) (€) | -0.283 | ||
| Beta | 1.627 | ||
| 3-Year Sharpe Ratio | -0.39 | ||
| 3-Year Sortino Ratio | -0.57 | ||
| Volatility % | 80.34 | ||
| 14-Day RSI | 61.72 | ||
| 14-Day ATR (€) | 0.072806 | ||
| 20-Day SMA (€) | 0.9835 | ||
| 12-1 Month Momentum % | 17.14 | ||
| 52-Week Range (€) | 0.54 - 1.37 | ||
| Shares Outstanding (Mil) | 103.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MaxCyte Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MaxCyte Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 82 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 81 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 16:30 | 1.07 (+3.88%) | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 1.07 (+3.88%) | ||
| General meeting for 2026 | 2026-06-18 16:00 | 0.98 (+1.56%) | ||
| General meeting for 2026 | 2026-06-17 11:00 | 0.96 (-2.04%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 16:30 | 0.69 (-2.14%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 0.69 (-2.14%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 0.71 (+10.94%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 0.71 (+10.94%) |
Show
Entries
MaxCyte Inc Frequently Asked Questions
What is MaxCyte Inc(STU:MYE0)'s stock price today?
The current price of STU:MYE0 is €1.11. The 52 week high of STU:MYE0 is €1.37 and 52 week low is €0.54.
When is next earnings date of MaxCyte Inc(STU:MYE0)?
The next earnings date of MaxCyte Inc(STU:MYE0) is 2026-11-06 Est..
Does MaxCyte Inc(STU:MYE0) pay dividends? If so, how much?
MaxCyte Inc(STU:MYE0) does not pay dividend.
Press Release
Articles on MaxCyte Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers